Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 2. EEG-tomography findings based on LORETA (low-resolution brain electromagnetic tomography).
Effects of ABIO-08/01, a new potentially anxiolytic isoxazoline, on regional electrical brain generators were investigated by 3-dimensional EEG tomography. In a double- blind, placebo-controlled, multiple-ascending-dose study, 16 healthy males (30.2 +/- 5.7 years) received 3 oral drug doses (10, 20, 40 mg) and placebo for 7 days (8-day wash-out) in a randomized non-balanced design for phase-1 studies. A 3-min vigilance-controlled (V) EEG, a 4-min resting (R) EEG with eyes closed, a 1-min eyes-open (EO) EEG and psychometric tests were performed 0, 1 and 6 h after taking the drug on days 1 and 5. Low-resolution brain electromagnetic tomography (LORETA) was computed from the spectrally analyzed EEG data, and differences between drug and placebo were displayed as statistical parametric maps. Data were registered to the Talairach-Tournoux Human Brain Atlas available as a digitized MRI. An overall omnibus significance test followed by a voxel-by-voxel t test demonstrated significant regional EEG changes after ABIO-08/01 versus placebo, dependent on recording condition, dose and time. While in the EO-EEG specifically the lowest dose of ABIO-08/01 induced pronounced sedative effects (delta/theta and beta increase) 1 h after acute and slightly less so after superimposed administration, in the 6th hour a decrease in alpha and beta activity signaled less sedative and more relaxant action. In the V-EEG these changes were less pronounced, in the R-EEG partly opposite. Hemisphere-specific changes were observed, suggesting increases in LORETA power over the left temporal, parietal, superior frontal regions and decreases over the right prefrontal, temporal pole and occipital regions. These LORETA changes are discussed in the light of neuroimaging findings on anxiety and anxiolytics.
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. bernd.saletu@meduniwien.ac.at
Bernd
B
Saletu
Peter
P
Anderer
Michael
M
Wolzt
Dorothea
D
Nosiska
Alessandro
A
Assandri
Emanuele
E
Noseda
Fabrizio
F
Nannipieri
Gerda M
GM
Saletu-Zyhlarz
D000328:Adult; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001931:Brain Mapping; D002540:Cerebral Cortex / Q000187:drug effects* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004569:Electroencephalography / Q000187:drug effects*; D006624:Hippocampus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology*; D008297:Male; D010919:Placebos; D011597:Psychomotor Performance / Q000187:drug effects; D013997:Time Factors; D014054:Tomography / Q000379:methods*
C529993:ABIO 0801; D014151:Anti-Anxiety Agents; D007555:Isoxazoles; D010919:Placebos